Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q96EH3
UPID:
MASU1_HUMAN
Alternative names:
-
Alternative UPACC:
Q96EH3; A4D154
Background:
Mitochondrial assembly of ribosomal large subunit protein 1 is pivotal for mitochondrial ribosome function and translation. It prevents premature association of ribosomal subunits and interacts with MRPL14, blocking bridge B8 formation. This protein is essential for ribosome biogenesis, mitochondrial translation, and may act as a ribosomal silencing factor.
Therapeutic significance:
Understanding the role of Mitochondrial assembly of ribosomal large subunit protein 1 could open doors to potential therapeutic strategies.